Drugs / Human Heterologous Liver Cells
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Heparesc | — | 2015-12-21 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00718627 | Jul 2008 → Nov 2015 | carbamoyl phosphate synthetase I deficiency disease, citrullinemia, ornithine carbamoyltransferase deficiency | Cytonet GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Heterologous Liver Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00718627 ↗ |
| Route | Other | “Multiple applications of liver cell suspension into The Portal Vein” NCT00718627 ↗ |